LYSOGENE

Their core work

Lysogene is a French clinical-stage biotechnology SME specializing in gene therapy for severe diseases of the central nervous system, particularly rare genetic conditions. Within H2020 consortia, they contribute industry expertise on advanced therapy development, regulatory strategy for market access, and real-world experience navigating reimbursement pathways. Their participation spans from shaping adaptive drug approval frameworks to accelerating rare disease diagnosis through genetic screening and digital tools.

What they specialise in

How they've shifted over time

Lysogene's H2020 trajectory shows a clear shift from process to product. Their early involvement (ADAPT-SMART, 2015-2018) focused on the regulatory and reimbursement infrastructure needed to bring advanced therapies to market — adaptive trial design, HTA, and multi-party collaboration models. From 2020 onward, they moved squarely into the therapies themselves: gene and cell therapy development (ARDAT) and rare disease diagnosis via genetic screening and digital platforms (SCREEN4CARE). This evolution suggests an organization that first invested in understanding the approval landscape and is now applying that knowledge to advance its own therapeutic pipeline.

Lysogene is deepening its focus on rare disease gene therapy while expanding into digital diagnostic tools and newborn screening — expect continued interest in projects that bridge advanced therapies with early patient identification.

How they like to work

Lysogene operates exclusively as a consortium participant, never as coordinator, which is typical of a focused biotech SME that contributes specialized industry knowledge rather than managing large projects. With 93 unique partners across 19 countries from just 3 projects, they participate in large, multi-national consortia — their projects likely involve 30+ partners each. This means they are comfortable in complex collaborative environments and bring a specific, valued perspective (industry/commercial) rather than broad research capacity.

Despite only three projects, Lysogene has built connections with 93 distinct partners across 19 countries, reflecting participation in very large European health consortia. Their network spans the continent broadly rather than clustering in any single region.

What sets them apart

Lysogene brings a rare combination: they are an active gene therapy developer (with their own clinical pipeline) who also understands the regulatory and reimbursement landscape from their ADAPT-SMART experience. For consortium builders, this means a partner who can contribute both scientific substance on advanced therapies and practical insight on how to get those therapies approved and paid for. As an SME, they also satisfy SME participation requirements while offering genuine deep expertise rather than token involvement.

Highlights from their portfolio

• SCREEN4CARE
  Combines newborn genetic screening with machine-learning diagnostics to shorten rare disease diagnosis — a convergence of genomics and AI that is highly current.
• ARDAT
  Large-scale initiative (running to 2026) accelerating gene and cell therapy development, placing Lysogene at the center of Europe's advanced therapy ecosystem.
• ADAPT-SMART
  Addressed the fundamental challenge of getting innovative therapies through regulatory and reimbursement systems — foundational knowledge that informs all of Lysogene's later work.